Italian-based Stevanato Group, a producer of pharmaceutical glass containers and integrated provider of drug delivery systems, is preparing to open its Technology Excellence Center in Boston (US TEC), MA.
 
To respond to the growing demand in U.S. biologics for integrated analytical offerings and project management services, Stevanato Group is establishing the Boston-based site.
 
 The new center will provide a full-service approach to support biopharmas along their drug development journey, from the early phase to commercialization and lifecycle management.
 
Set to open its doors in late September, the US TEC will support biopharma drug development throughout the lifecycle, helping them overcome the challenges of the container-closure system.
 
“R&D represents a key driver for Stevanato Group’s growth. From its outset, the US TEC will advise on materials science, chemistry, and engineering performing many added value analytical tests focusing on container closure characterization as well as fill and finish development and optimization. In the second phase, we will be adding customized solutions dedicated to product development and functional testing of primary containers and drug delivery devices. Located in the cradle of biotech, US TEC can easily integrate within the product development team and the value chain of our local customers,” said Paolo Patri, chief technology officer, Stevanato Group.
 
To support today’s increasingly urgent need for treatments and vaccines related to COVID-19, Stevanato Group has deployed all its available assets to ensure the availability of state-of-the-art glass vials and syringes, plastics diagnostic consumables, equipment, and analytical testing.
 
Abizer Harianawala, site leader at Stevanato Group’s US TEC, said, “As pharma companies are under pressure to find more effective and safer treatments rapidly, more clinical trials take place, and new emerging therapies are developed and tested. Being in the U.S., we can offer timely solutions for robust product development for these therapies. With our dedicated team of subject matter experts, we work as a single point of contact coordinating internal resources and our best-in-class network of partners and consultants.”